- Home
- SCS vs CPRX Comparison
SCS vs CPRX Comparison
Compare SCS & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCS
- CPRX
- Stock Information
- Founded
- SCS 1912
- CPRX 2002
- Country
- SCS United States
- CPRX United States
- Employees
- SCS N/A
- CPRX N/A
- Industry
- SCS Office Equipment/Supplies/Services
- CPRX Biotechnology: Pharmaceutical Preparations
- Sector
- SCS Consumer Discretionary
- CPRX Health Care
- Exchange
- SCS Nasdaq
- CPRX Nasdaq
- Market Cap
- SCS 1.5B
- CPRX 2.4B
- IPO Year
- SCS 1998
- CPRX 2006
- Fundamental
- Price
- SCS $13.21
- CPRX $21.15
- Analyst Decision
- SCS Strong Buy
- CPRX Strong Buy
- Analyst Count
- SCS 2
- CPRX 6
- Target Price
- SCS $17.00
- CPRX $29.50
- AVG Volume (30 Days)
- SCS 586.3K
- CPRX 936.6K
- Earning Date
- SCS 12-17-2024
- CPRX 11-06-2024
- Dividend Yield
- SCS 3.05%
- CPRX N/A
- EPS Growth
- SCS 125.40
- CPRX N/A
- EPS
- SCS 1.06
- CPRX 0.58
- Revenue
- SCS $3,136,200,000.00
- CPRX $434,475,000.00
- Revenue This Year
- SCS $3.59
- CPRX $21.33
- Revenue Next Year
- SCS $3.54
- CPRX $17.29
- P/E Ratio
- SCS $12.46
- CPRX $36.45
- Revenue Growth
- SCS N/A
- CPRX 43.42
- 52 Week Low
- SCS $10.29
- CPRX $11.89
- 52 Week High
- SCS $14.74
- CPRX $21.85
- Technical
- Relative Strength Index (RSI)
- SCS 51.58
- CPRX 64.52
- Support Level
- SCS $12.82
- CPRX $19.54
- Resistance Level
- SCS $13.24
- CPRX $21.85
- Average True Range (ATR)
- SCS 0.27
- CPRX 0.49
- MACD
- SCS 0.04
- CPRX 0.14
- Stochastic Oscillator
- SCS 71.90
- CPRX 82.40
About SCS Steelcase Inc.
Steelcase Inc is a furniture company based in the United States. Its brands such as Steelcase, AMQ, Coalesse, Designtex, and others offer a portfolio of furniture and architectural products and services designed to help customers create workplaces. It markets its products and services to businesses and organizations predominantly through a network of dealers and also sells to consumers in markets around the world through web-based and retail distribution channels. The company's reportable segments include the Americas which generates key revenue, and International.
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.